Melanoma & Skin Cancer | Specialty

FDA Approves Vemurafenib/Cobimetinib Combo for Melanoma

November 10th 2015

The FDA has approved the combination of vemurafenib and cobimetinib as a treatment for patients with metastatic or unresectable BRAF V600E/K mutation-positive melanoma.

Adjuvant Ipilimumab Approval, Two Breakthrough Designations, and More

November 9th 2015

Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval

November 6th 2015

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes.

BRAF/MEK Combination Highly Effective in Melanoma

November 6th 2015

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

Dr. Weber on Dabrafenib/Trametinib Approval for Melanoma

November 6th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Targeted Therapy Combinations Still Key in Metastatic Melanoma

November 5th 2015

Combinations of targeted therapies continue to advance toward full regulatory approval for patients with metastatic or unresected melanoma, given the substantial benefits seen with these agents.

FDA Approves Adjuvant Ipilimumab in Melanoma

October 28th 2015

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

FDA Approves T-VEC for Advanced Melanoma

October 27th 2015

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

CHMP Recommends T-VEC Approval for Melanoma

October 23rd 2015

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

Hedgehog Pathway Remains a Ripe Target in Many Malignancies

October 21st 2015

The Hedgehog pathway is one of several key developmental cell-signaling networks whose aberrant activation in adult tissues can lead to cancer.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

Cobimetinib/Vemurafenib Combo Improves Survival in Melanoma

October 6th 2015

The combination of vemurafenib and cobimetinib demonstrated a statistically significant improvement in overall survival compared with vemurafenib alone for previously untreated patients with BRAFV600-mutant unresectable or metastatic melanoma.

FDA Approves Nivolumab/Ipilimumab Combination for BRAF Wild-Type Melanoma

October 1st 2015

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab as a treatment for patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Dabrafenib/Trametinib Combo Improves OS Versus Vemurafenib in Advanced Melanoma

September 27th 2015

The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.

T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma

September 27th 2015

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

FDA Grants Nivolumab/Ipilimumab Combination Priority Review for Advanced Melanoma

September 26th 2015

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Jeffrey Weber Joins NYU Langone, Plans to Expand Clinical Trial and Immunotherapy Initiatives

September 25th 2015

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.